StockNews rates FibroGen (FGEN) a "hold", while its CEO and other insiders buy shares of FibroBiologics (FBLG).

StockNews covers FibroGen (NASDAQ: FGEN), giving it a "hold" rating. FGEN's stock opened at $0.39 with a market cap of $38.30M. The company reported EPS of ($0.16) for Q, beating estimates by $0.09. Its products include Phase III cancer and anemia treatments. StockNews also reports insider purchases for FibroBiologics (NASDAQ: FBLG), including CEO Pete O'Heeron and Hamid Khoja, both buying shares on August 12th.

August 13, 2024
3 Articles

Further Reading